Insider Selling: Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells 15,000 Shares of Stock

Key Points

• Insider sale: Director Brian Daniel Webster sold 15,000 KMTS shares on April 15 at an average price of $20.04 for $300,600, cutting his stake by 4.11% to 349,786 shares; he also sold 15,000 shares on Feb. 17 and 15,000 on Mar. 17, totaling 45,000 shares recently.
• Stock and analyst context: KMTS traded at $20.41 (+1.1%) with a market cap of about $1.19B and strong revenue growth (62.7% YoY) but negative earnings, while analysts are mixed—average rating "Hold" and average target $27.40, with targets ranging from $17 (Goldman) to $32 (BTIG).

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $20.04, for a total transaction of $300,600.00. Following the transaction, the insider owned 349,786 shares in the company, valued at $7,009,711.44. This trade represents a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Brian Daniel Webster also recently made the following trade(s):

• On Tuesday, March 17th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.27, for a total transaction of $304,050.00.
• On Tuesday, February 17th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $25.60, for a total transaction of $384,000.00.

Kestra Medical Technologies Stock Up 1.1%

Shares of KMTS stock traded up $0.22 during trading hours on Thursday, hitting $20.41. 228,451 shares of the company were exchanged, compared to its average volume of 339,997. The stock has a market capitalization of $1.19 billion and a price-to-earnings ratio of -5.15. Kestra Medical Technologies, Ltd. has a one year low of $13.25 and a one year high of $30.00. The business's 50-day simple moving average is $22.32 and its two-hundred day simple moving average is $24.32. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.32 and a current ratio of 7.32.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last released its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.01). The firm had revenue of $24.55 million during the quarter. Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.The business's revenue was up 62.7% on a year-over-year basis.

Institutional Investors Weigh In On Kestra Medical Technologies

Institutional investors have recently made changes to their positions in the company. Farther Finance Advisors LLC bought a new position in shares of Kestra Medical Technologies during the 4th quarter valued at $31,000. Russell Investments Group Ltd. raised its holdings in Kestra Medical Technologies by 43.5% during the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company's stock valued at $41,000 after buying an additional 474 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Kestra Medical Technologies during the 3rd quarter worth about $48,000. Daiwa Securities Group Inc. acquired a new position in shares of Kestra Medical Technologies during the 4th quarter valued at about $72,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company's stock valued at $65,000 after acquiring an additional 1,638 shares during the last quarter.

Analysts Set New Price Targets

A number of brokerages have issued reports on KMTS. The Goldman Sachs Group reduced their price target on Kestra Medical Technologies from $22.00 to $17.00 and set a "neutral" rating for the company in a research report on Thursday, April 9th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Kestra Medical Technologies in a report on Monday, March 23rd. Finally, BTIG Research reiterated a "buy" rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a research report on Tuesday, April 7th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Kestra Medical Technologies has an average rating of "Hold" and an average price target of $27.40.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.